{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:52:05Z","timestamp":1787014325389,"version":"build-2736575974"},"reference-count":48,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":723,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1111\/ijcp.12298","type":"journal-article","created":{"date-parts":[[2013,9,8]],"date-time":"2013-09-08T21:35:56Z","timestamp":1378676156000},"page":"1089-1104","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?"],"prefix":"10.1155","volume":"67","author":[{"given":"L.","family":"Citrome","sequence":"first","affiliation":[{"name":"New York Medical College; Valhalla NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,8]]},"reference":[{"key":"10.1111\/ijcp.12298-BIB0001|ijcp12298-cit-0001","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.neuropharm.2013.02.024","article-title":"Levomilnacipran\u00a0(F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety","volume":"70","author":"Auclair","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1111\/ijcp.12298-BIB0002|ijcp12298-cit-0002","unstructured":"Forest Laboratories, Inc. Forest Laboratories and Pierre Fabre Laboratories announce FDA approval of FETZIMA for the treatment of major depressive disorder in adults. Press Release 2013 http:\/\/frx.investorhq.businesswire.com\/press-release\/corporate-news\/forest-laboratories-and-pierre-fabre-laboratories-announce-fda-approval"},{"key":"10.1111\/ijcp.12298-BIB0003|ijcp12298-cit-0003","unstructured":"Forest Pharmaceuticals, Inc FETZIMA (levomilnacipran). Prescribing information 2013 http:\/\/www.frx.com\/pi\/Fetzima_pi.pdf"},{"key":"10.1111\/ijcp.12298-BIB0004|ijcp12298-cit-0004","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/BF03189334","article-title":"Which bioequivalence study for a racemic drug? Application to milnacipran","volume":"23","author":"Deprez","year":"1998","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1111\/ijcp.12298-BIB0005|ijcp12298-cit-0005","doi-asserted-by":"crossref","first-page":"8111","DOI":"10.1039\/c2cc33743f","article-title":"Enantioselective synthesis of levomilnacipran","volume":"48","author":"Alliot","year":"2012","journal-title":"Chem Commun (Camb)"},{"key":"10.1111\/ijcp.12298-BIB0006|ijcp12298-cit-0006","unstructured":"Forest Pharmaceuticals, Inc Savella (milnacipran HCl) tablets. Prescribing information 2012 http:\/\/www.frx.com\/pi\/Savella_pi.pdf"},{"key":"10.1111\/ijcp.12298-BIB0007|ijcp12298-cit-0007","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00131746-200403000-00006","article-title":"Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor","volume":"10","author":"Preskorn","year":"2004","journal-title":"J Psychiatr Pract"},{"key":"10.1111\/ijcp.12298-BIB0008|ijcp12298-cit-0008","doi-asserted-by":"crossref","unstructured":"Gelenberg AJ Freeman MP Markowitz JC Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition American Psychiatric Association 2010 10.1176\/appi.books.9780890423387.654001","DOI":"10.1176\/appi.books.9780890423387.654001"},{"issue":"4","key":"10.1111\/ijcp.12298-BIB0009|ijcp12298-cit-0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3810\/pgm.2010.07.2174","article-title":"Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"122","author":"Citrome","year":"2010","journal-title":"Postgrad Med"},{"key":"10.1111\/ijcp.12298-BIB0010|ijcp12298-cit-0010","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/JCP.0b013e3181a5233f","article-title":"Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis","volume":"29","author":"Serretti","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12298-BIB0011|ijcp12298-cit-0011","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4088\/JCP.09r05346blu","article-title":"Antidepressants and body weight: a comprehensive review and meta-analysis","volume":"71","author":"Serretti","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12298-BIB0012|ijcp12298-cit-0012","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4088\/JCP.12m08141","article-title":"Efficacy and safety of\u00a0levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study","volume":"74","author":"Montgomery","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12298-BIB0013|ijcp12298-cit-0013","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4088\/JCP.12m08197","article-title":"Efficacy and safety of\u00a0levomilnacipran\u00a0sustained release 40\u00a0mg, 80\u00a0mg, or 120\u00a0mg in major depressive disorder: a Phase 3, randomized, double-blind, placebo-controlled study","volume":"74","author":"Asnis","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12298-BIB0014|ijcp12298-cit-0014","unstructured":"Gommol C Bose A Li H Edwards J A randomized double-blind, placebo-controlled, flexible-dose study of levomilnacipran in patients with major depressive disorder Poster, US Psychiatric and Mental Health Congress 24th Annual Meeting Las Vegas, NV 2011"},{"issue":"Suppl.","key":"10.1111\/ijcp.12298-BIB0015|ijcp12298-cit-0015","first-page":"S322","article-title":"A Phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran SR in patients with major depressive disorder","volume":"38","author":"Sambunaris","year":"2012","journal-title":"Neuropsychopharmacology"},{"issue":"Suppl.","key":"10.1111\/ijcp.12298-BIB0016|ijcp12298-cit-0016","first-page":"S427","article-title":"Levomilnacipran SR 40\u00a0mg and 80\u00a0mg in major depressive disorder: a Phase III, randomized, double-blind, fixed-dose, placebo-controlled study","volume":"38","author":"Bakish","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"10.1111\/ijcp.12298-BIB0017|ijcp12298-cit-0017","doi-asserted-by":"crossref","unstructured":"Mago R Forero G Greenberg WM Bose A Gommoll C Chen C Safety and tolerability of levomilnacipran SR in major depressive disorder: results from an open-label, 48-week extension study New Research Poster NR9-42, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013","DOI":"10.1016\/S0924-977X(13)70519-4"},{"key":"10.1111\/ijcp.12298-BIB0018|ijcp12298-cit-0018","unstructured":"Shiovitz T Bose A Greenberg WM The efficacy and safety of levomilnacipran SR in the prevention of relapse in major depressive disorder: results from a Phase III clinical trial Poster, US Psychiatric and Mental Health Congress 25th Annual Meeting San Diego, CA 2012"},{"key":"10.1111\/ijcp.12298-BIB0019|ijcp12298-cit-0019","doi-asserted-by":"crossref","unstructured":"Montgomery S Bose A Gommoll C Chen C Levomilnacipran SR efficacy in major depressive disorder across patient subgroups: pooled analyses of 5 double-blind, placebo-controlled trials New Research Poster NR9-29, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013","DOI":"10.1016\/S0924-977X(13)70528-5"},{"key":"10.1111\/ijcp.12298-BIB0020|ijcp12298-cit-0020","doi-asserted-by":"crossref","unstructured":"Sambunaris A Bose A Gommoll C Chen C Levomilnacipran SR and functional efficacy in major depressive disorder: a pooled analyses of 5 double-blind, placebo-controlled trials Poster Presentation II-39, 53rd Annual NCDEU Meeting Hollywood, FL 2013","DOI":"10.1016\/S0924-977X(13)70529-7"},{"key":"10.1111\/ijcp.12298-BIB0021|ijcp12298-cit-0021","unstructured":"Thase ME Greenberg WM Bose A Gommoll C Chen C Safety and tolerability of levomilnacipran SR in major depressive disorder: analysis of 5 short-term double-blind, placebo-controlled trials New Research Poster NR10-53, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013"},{"key":"10.1111\/ijcp.12298-BIB0022|ijcp12298-cit-0022","doi-asserted-by":"crossref","unstructured":"Blum SI Tourkodimitris S Gommoll C Bose A Thase ME Sustained improvement in functional health and well-being in MDD patients following long-term treatment with levomilnacipran SR Poster Presentation II-58, 53rd Annual NCDEU Meeting Hollywood, FL 2013","DOI":"10.1016\/j.jval.2013.03.1553"},{"key":"10.1111\/ijcp.12298-BIB0023|ijcp12298-cit-0023","doi-asserted-by":"crossref","unstructured":"Gommoll C Bose A Chen C Citrome L Effects of levomilnacipran SR 40, 80, and 120\u00a0mg on functional outcomes in major depressive disorder: post hoc analyses of a Phase III trial New Research Poster NR9-19, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013","DOI":"10.1016\/S0924-977X(13)70517-0"},{"key":"10.1111\/ijcp.12298-BIB0024|ijcp12298-cit-0024","unstructured":"Wesnes K Bose A Gommoll C Chen C Effects of levomilnacipran SR on measures of attention in a Phase 3 trial of major depressive disorder Poster Presentation I-66, 53rd Annual NCDEU Meeting Hollywood, FL 2013"},{"key":"10.1111\/ijcp.12298-BIB0025|ijcp12298-cit-0025","unstructured":"Chen L Periclou A Ghahramani P Greenberg WM Brand-Schieber E Pharmacokinetic characteristics of levomilnacipran sustained release capsule following single- and multiple-dose administration New Research Poster NR9-17, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013"},{"key":"10.1111\/ijcp.12298-BIB0026|ijcp12298-cit-0026","unstructured":"Carrothers TJ Chen C Chen L Population pharmacokinetic modeling to assess the impact of baseline covariates on levomilnacipran exposures in patients with major depressive disorder Poster Presentation II-59, 53rd Annual NCDEU Meeting Hollywood, FL 2013"},{"key":"10.1111\/ijcp.12298-BIB0027|ijcp12298-cit-0027","unstructured":"Chen L Boinpally R Gad N Periclou A Ghahramani P Greenberg WM Drug-drug interactions of levomilnacipran sustained release capsule with ketoconazole, carbamazepine, or alprazolam in healthy subjects New Research Poster NR9-16, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013"},{"key":"10.1111\/ijcp.12298-BIB0028|ijcp12298-cit-0028","unstructured":"Palmer R Shrestha P Greenberg WM Cardiovascular safety profile of levomilnacipran SR in the treatment of major depressive disorder New Research Poster NR9-12, American Psychiatric Association 166th Annual Meeting San Francisco, CA 2013"},{"key":"10.1111\/ijcp.12298-BIB0029|ijcp12298-cit-0029","unstructured":"Chen L Boinpally R Gad N Periclou A Ghahramani P Greenberg WM A single-dose pharmacokinetic study of levomilnacipran SR in subjects with normal and impaired hepatic function Poster Presentation I-41, 53rd Annual NCDEU Meeting Hollywood, FL 2013"},{"key":"10.1111\/ijcp.12298-BIB0030|ijcp12298-cit-0030","unstructured":"Chen L Carrothers TJ Periclou A Ghahramani P Greenberg WM Brand-Schieber E. A single-dose pharmacokinetic study of levomilnacipran SR in subjects with normal or impaired renal function Poster Presentation II-64, 53rd Annual NCDEU Meeting Hollywood, FL 2013"},{"key":"10.1111\/ijcp.12298-BIB0031|ijcp12298-cit-0031","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1600-0447.2008.01194.x","article-title":"Compelling or irrelevant? Using number needed to treat can help decide","volume":"117","author":"Citrome","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.12298-BIB0032|ijcp12298-cit-0032","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf"},{"key":"10.1111\/ijcp.12298-BIB0033|ijcp12298-cit-0033","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1742-1241.2011.02885.x","article-title":"Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"66","author":"Citrome","year":"2012","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12298-BIB0034|ijcp12298-cit-0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.jad.2013.06.027","article-title":"Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed","author":"Citrome","year":"2013","journal-title":"J Affect Disord"},{"key":"10.1111\/ijcp.12298-BIB0035|ijcp12298-cit-0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/ijcp.12142","article-title":"When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed","volume":"67","author":"Citrome","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1111\/ijcp.12298-BIB0036|ijcp12298-cit-0036","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1586\/14737175.8.7.1079","article-title":"Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks","volume":"8","author":"Citrome","year":"2008","journal-title":"Expert Rev Neurother"},{"key":"10.1111\/ijcp.12298-BIB0037|ijcp12298-cit-0037","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00023210-200822070-00004","article-title":"Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants: a systematic review and meta-analysis","volume":"22","author":"Nakagawa","year":"2008","journal-title":"CNS Drugs"},{"key":"10.1111\/ijcp.12298-BIB0038|ijcp12298-cit-0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3325\/cmj.2010.51.61","article-title":"Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials","volume":"51","author":"Trkulja","year":"2010","journal-title":"Croat Med J"},{"key":"10.1111\/ijcp.12298-BIB0039|ijcp12298-cit-0039","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S146114571000115X","article-title":"Efficacy of\u00a0escitalopram\u00a0compared to\u00a0citalopram: a\u00a0meta-analysis","volume":"14","author":"Montgomery","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12298-BIB0040|ijcp12298-cit-0040","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00004850-200609000-00004","article-title":"Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat","volume":"21","author":"Cookson","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"145-6","key":"10.1111\/ijcp.12298-BIB0041|ijcp12298-cit-0041","first-page":"154","article-title":"Psychopharmacology: number needed to treat: an underused measure of treatment effect","volume":"54","author":"Pinson","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1111\/ijcp.12298-BIB0042|ijcp12298-cit-0042","doi-asserted-by":"crossref","first-page":"B49","DOI":"10.1016\/j.clinthera.2011.11.019","article-title":"Solving the antidepressant efficacy question? Effect sizes in major depressive disorder","volume":"33","author":"V\u00f6hringer","year":"2011","journal-title":"Clin Ther"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12298-BIB0043|ijcp12298-cit-0043","first-page":"15","article-title":"The\u00a0noradrenergic symptom cluster: clinical expression and neuropharmacology","volume":"7","author":"Blier","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"Suppl. 1","key":"10.1111\/ijcp.12298-BIB0044|ijcp12298-cit-0044","first-page":"21","article-title":"Improvement of the\u00a0noradrenergic symptom cluster\u00a0following treatment with milnacipran","volume":"7","author":"Kasper","year":"2011","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1111\/ijcp.12298-BIB0045|ijcp12298-cit-0045","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of\u00a0antidepressants","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr"},{"key":"10.1111\/ijcp.12298-BIB0046|ijcp12298-cit-0046","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.biopsych.2007.03.027","article-title":"Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents","volume":"62","author":"Papakostas","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1111\/ijcp.12298-BIB0047|ijcp12298-cit-0047","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1017\/S1092852900020320","article-title":"Escitalopram versus\u00a0SNRI\u00a0antidepressants in the acute treatment of major depressive disorder: integrative analysis of four double-blind, randomized clinical trials","volume":"14","author":"Kornstein","year":"2009","journal-title":"CNS Spectr"},{"key":"10.1111\/ijcp.12298-BIB0048|ijcp12298-cit-0048","doi-asserted-by":"crossref","first-page":"e1014","DOI":"10.1136\/bmj.e1014","article-title":"Choosing a second generation\u00a0antidepressant\u00a0for treatment of\u00a0major depressive disorder","volume":"344","author":"Lester","year":"2012","journal-title":"BMJ"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12298","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T01:07:09Z","timestamp":1643332029000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,8]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2013,11]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12298","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,8]]},"assertion":[{"value":"2013-09-08","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}